
Astronomers capture images of the birth of a distant planet
Planets are formed from spinning halos of hot material known as protoplanetary discs , which form around very young stars. As planets start to form, they 'sweep' their orbits to produce intricate patterns of rings, gaps, and spirals in the dust. Although astronomers have spotted these patterns in the past, this is the first time anyone has caught one of these planetary sculptures in the act. Lead author Francesco Maio, a doctoral researcher at the University of Florence, says: 'We will never witness the formation of Earth, but here, around a young star 440 light–years away, we may be watching a planet come into existence in real time.'
The European Southern Observatory's Very Large Telescope (VLT) first spotted the spiral patterns around HD 135344B back in 2016. However, the equipment used in those early studies wasn't sensitive enough to confirm whether there was a protoplanet – the first stage of planetary formation – within the rings. In a new study, published today in the journal Astronomy and Astrophysics, researchers have used the VLT's new Enhanced Resolution Imager and Spectrograph (ERIS) to pinpoint the planet's likely location. Mr Maio and his co–authors spotted a 'planet candidate' – something strongly believed to be a planet – right at the base of one of the disc's spiral arms.
If these spirals were caused by a planet disturbing the ring of dust, that is exactly where astronomers would expect the planet to be. What makes these observations so special is that the astronomers were actually able to capture light coming directly from the planet itself. This is a significant piece of evidence in favour of the theory that gaps and rings in protoplanetary disks around other stars are hiding protoplanets of their own. Mr Maio says: 'What makes this detection potentially a turning point is that, unlike many previous observations, we are able to directly detect the signal of the protoplanet, which is still highly embedded in the disc.
These observations could also help shed light on how the planets in our own solar system formed over four billion years ago. At the same time, a second group of researchers have used ERIS to spot another potential planet forming around another young, distant star. V960 Mon sits roughly 5,000 light years from Earth and is believed to be extremely young. When astronomers first found captured images of it in 2023, they found that the star was spitting out arms of gas and dust wider than our entire Milky Way.
In this new study, astronomers found that the spiral arms are 'fragmenting' in a way that suggests a process known as 'gravitational instability' is at play. Planets normally form like snowballs rolling down a hill, as matter collides and clumps together into ever bigger lumps – this is known as core accretion. But sometimes, when the gas and dust are cooler and further from the host star, matter will slowly pull itself together under gravity and form clumps that collapse into the core of a planet. Scientists believe this is how gas giants like Jupiter and Saturn typically form.
If this is what has caused the fragmentation around V960 Mons, it would be the first time that anyone has ever seen a planet forming via gravitational instability. However, astronomers now say that something even stranger could be lurking around V960 Mons. The researchers believe that the object could be a 'brown dwarf', an object bigger than a planet that didn't gain enough mass to shine as a star. These giant planets can be between 13 and 80 times the size of Jupiter and typically orbit far out from their companion stars. Likewise, no one has yet captured the exact moment that one of these mysterious objects comes into existence.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
an hour ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.


BBC News
8 hours ago
- BBC News
Sellafield robotic arms to decommission nuclear gloveboxes
A development in robotic technology could be the answer to cleaning up hundreds of nuclear devices collected over in Cumbria, Europe's largest nuclear plant, has built up a stack of 700 gloveboxes - sealed containers with built in gloves that allow operators to handle radioactive are up to 60 years old, vary in size and shape and still contain contaminated materials like pipework and valves.A team of robotics experts has developed a dextrous mechanised arm that can be fitted inside an active nuclear glovebox to help tackle the challenging task of cleaning up and disposing of these devices. Known as the Risk Reduction of Glovebox Operations (RrOBO) project, it was developed in partnership with AtkinsRéalis, Cavendish Nuclear and Taylor Kightley Engineering."Removing hands from gloveboxes is a key challenge for the nuclear industry and we're proud to be helping to drive change and improve safety," said Robert Marwood, from AtkinsRé proved the robotic arm could successfully carry out a complex series of tasks safely, meaning the technology can now be deployed to legacy gloveboxes to accelerate decommissioning. A spokesman for Sellafield, which opened in 1947 and has the largest stockpile of radioactive plutonium in the world, said some of its older labs contained gloveboxes dating back decades, taking up space and posing "a potential hazard to workers and the environment"It started running a glovebox training facility this year to help meet demand for the spokesman said: "We'll need a pipeline of skilled glovebox operators for many years to come, but it's difficult work requiring high levels of dexterity and consistent standards."They added the nuclear industry nationally needed thousands of new gloveboxes to support "current and future missions in the decommissioning and defence sectors." Follow BBC Cumbria on X, Facebook, Nextdoor and Instagram.


Telegraph
9 hours ago
- Telegraph
New contraceptive pill for men is safe, study suggests
A new male contraceptive pill tested on British men in a world first is safe for use, a study suggests. Oral female contraceptive tablets have been available for 60 years but there has never been an authorised male version. Female tablets work by altering hormone levels to reduce the risk of conception but this approach has proven difficult in men because of severe side effects such as infertility and mood swings. These side effects are common in female versions. A third of men say they would take a contraceptive pill if one was available to them. YourChoice Therapeutics has developed the first non-hormonal contraceptive for men which works by blocking the production of a protein, which is needed to produce sperm, and not meddling with hormones. The drug stops production of retinoic acid receptor alpha (RAR-alpha) in the body and this prevents it binding to vitamin A compounds and subsequently prevents sperm production. Animal studies showed this mechanism to be 99 per cent effective and also found that sperm levels returned to normal after the medication was stopped, showing the contraceptive to be temporary and reversible. Human trials began in 2023 when 16 healthy men who had already had a vasectomy were recruited to test the safety of the drug in people. Data, published this week, show it to be safe and well-tolerated with no clinically relevant side effects in a significant step forward for the prospects of the drug, known as YCT-529. The trial of 16 British men gave participants either the tablet or a placebo and conducted analysis on the participants to measure their blood, urine, mood and overall health. Four different dosages were tested and all were found to be well-tolerated. The highest dose was the same as what was shown to be effective as a contraceptive in animal trials. 'Positive results' There was no reduction in testosterone levels, sex drive or any other hormonal imbalance, the scientists found. 'The positive results from this first clinical trial laid the groundwork for a second trial, where men receive YCT-529 for 28 days and 90 days, to study safety and changes in sperm parameters,' the study authors write in their peer-reviewed study in the journal Communications Medicine. Further trials will now gather more data on the long-term safety profile of the drugs and if this is found to be acceptable, the next stage of clinical trials will begin to determine its precise effectiveness in humans. The data are needed before regulators can make a decision on whether a drug is safe and effective enough to be approved for human use. The study authors add that the safety bar for contraceptives is much higher and harder to reach than it is for drugs designed to cure or treat a disease because it is preventative and used by healthy people daily for a long period of time. 'More attractive to men' Akash Bakshi, a co-founder and the chief executive of YourChoice, has previously suggested the medicine, if approved, could be sent out alongside at-home testing kits for men to check their sperm levels are too low to cause pregnancy. He said: 'YCT-529 blocks a protein – not hormones – to prevent sperm production. We believe this will be more attractive to men, most of whom view pregnancy prevention as a shared responsibility even despite today's limited contraceptive options, which are permanent or only moderately effective. 'The dearth of options reinforces the centuries-old view that pregnancy prevention is 'a woman's responsibility'. It's not, and we're committed to advancing the first hormone-free birth control pill for men that's effective, convenient, and temporary.' While non-hormonal male contraceptives are in trials and at the early stage of development and testing, other hormone-powered alternatives are also in the works. A gel which is rubbed into the shoulders of a man every day is one such medicine and contains Nestorone (segesterone acetate) and testosterone. This lowers sperm counts in around eight weeks and is in testing currently on more than 200 men in the US. The gel is rubbed into the shoulders or shoulder blades because it is easy to reach for the user and it is also unlikely a child or woman would come into direct contact with the gel in this location. The hormones soak into the skin and are absorbed by the bloodstream. But accidental exposure to the gel could cause premature puberty in children and acne or excessive hair growth in women.